The cannabis industry has been flooded with many new players, but one thing remains the same, the need for cannabis or medical marijuana research. This research is needed to improve the current knowledge of cannabis, to expand the understanding of the plant, and to provide the scientific evidence to help the industry move forward.
There are over 100 known cannabinoids in the cannabis plant. While the most well known are tetrahydrocannabinol (THC) and cannabinol (CBN), the list of cannabinoids includes chemicals such as cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), and many others that have yet to be identified and the list is growing. These cannabinoids and others that have yet to be identified in the cannabis plant have been referred to as “phytocannabinoids”. Scientific research is beginning to reveal the characteristics of phytocannabinoids and what they do in the body.
Cannabinoids like CBD and THC are proving to be effective treatments for a wide range of diseases and disorders such as epilepsy, cancer, diabetes and more.
Researchers are learning that the cannabinoids found in cannabis go far beyond those most people are familiar with: tetrahydrocannabinol (THC), the plant’s main psychoactive cannabinoid, and cannabidiol (CBD), a nonpsychoactive compound that is thought to relieve pain, reduce anxiety, and induce sleep.
With more than 200 cannabinoids identified and more study being conducted, cannabis users are becoming more interested in what are known as “rare cannabinoids,” despite the fact that it is still unknown what advantages they may provide.
Cannabinoids work by interacting with the endocannabinoid system (ECS), which controls sleep, appetite, mood, memory, production, and fertility in the human body. The body produces endocannabinoids to keep internal processes running smoothly. They communicate with endocannabinoid receptors located throughout the body to alert the ECS to intervene. After endocannabinoids have completed their job, enzymes break them down.
Rare cannabinoids act as supplements to endocannabinoids, and more than 50 clinical trials have been conducted to far.
Rare cannabinoids including cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV) are believed to have greater medicinal qualities than THC and CBD and don’t have the high effects of THC.
Grove Inc., a hemp and wellness industry pioneer headquartered in Henderson, Nevada, produces a complete range of plant-based goods with an emphasis on sustainability and customer pleasure. Organic farmers, biochemists, organic chemists, mixologists, and culinary scientists make up the company’s team of wellness pioneers.
Grove is investigating how some of the uncommon cannabinoids may be utilized to improve health, although its main emphasis has been on extracting CBD from hemp.
CBG, for example, is known as the “mother of cannabinoids” and is thought to combat inflammation, discomfort, and nausea, as well as delay cancer cell proliferation.
CBN, a cannabinoid produced as THC matures, has been shown to be a powerful antibacterial agent that may be utilized to treat illnesses that antibiotics can’t treat. It’s also been proven to increase appetite, decrease inflammation, and alleviate glaucoma.
CBN may potentially be used to treat amyotrophic lateral sclerosis (ALS), often known as Lou Gehrig’s illness after the baseball star who was afflicted with it.
THCV is being researched as a weight-loss and obesity-management treatment. It’s said to curb hunger, enhance satiety, and speed up metabolism. It is thought to be helpful in the treatment of type 2 diabetes.
Grove’s purchase of VitaMedica, an online supplement retailer, on August 5, 2021 puts it in a strong position to compete in the vitamin and nutraceutical industry, addressing customers’ health and wellness requirements as it expands its use of rare cannabinoids in its products. It combines Grove’s manufacturing innovation with VitaMedica’s product line, which has been prescribed by thousands of physicians and serviced more than 1 million people, to create a network that Grove can use for clinical trials, studies, and ongoing hemp research.
Grove CEO Allan Marshall stated at the time of the purchase, “Our team at Grove acquired a fantastic business with an outstanding product line that has produced more than $10 million in sales over the last few years and we think has the potential for exponential development from here.” “With the arrival of Dr. (David) Rahm, Yvette LaGarde, and their whole staff, we at Grove are most thrilled about the team members we acquired. I think that the people you acquire when you buy a business are essential to the success of the combined company.”
A new study has been published that has been searching for those magical compounds that have been the subject of a lot of buzz in the cannabis community over the past year. The study, which was conducted by a group of researchers from the University of South Florida, was published in the Journal of the American Osteopathic Association.. Read more about cbg scholarly articles and let us know what you think.
This article broadly covered the following related topics:
- is hemp and cbd the same
- what is cbd oil
- cbd oil side effects